Impax Generics: Bigger, Better, Bolder

Generic SupplementsGeneric Supplement 2015

Impax Generics continues to focus on the development, manufacture and commercialization of complex generic pharmaceutical products.

Impax Generics, formerly Global Pharmaceuticals, is the multiple-source products division of Impax Laboratories, Inc. Earlier in 2015, Impax completed the acquisition of Tower Holdings, Inc. Subsequently, two operating subsidiaries of Tower — CorePharma LLC and Lineage Therapeutics Inc. – were combined with Global Pharmaceuticals to form the newly named Impax Generics division. We have increased our commercial portfolio of products, broadened our R&D efforts and strengthened our generic pipeline. In addition, we have expanded and diversified our manufacturing, packaging and supply chain capabilities.

Our Portfolio

Impax Generics continues to focus on the development, manufacture and commercialization of complex generic pharmaceutical products, and our recent acquisition enhances this strategy. Our core competencies include expertise in controlled-release products, controlled substances and other difficult-to-formulate products. Using our controlled-release drug delivery technologies and formulation skills, we develop bioequivalent versions of selected brand name pharmaceuticals, many of which have technically challenging drug delivery requirements. Our specialty generics portfolio also includes the epinephrine injection, USP auto-injector, an authorized generic of Adrenaclick® (epinephrine injection, USP) auto-injector.

We bring value to our customers with innovative products in key therapeutic areas. We currently market 48 generic pharmaceutical products. The newest products in our portfolio include ursodiol tablets (equivalent to Urso® [ursodiol]) in two strengths, 250 mg and 500 mg, and metaxalone tablets (equivalent to Skelaxin® [metaxalone]) in the 400 mg strength.1

Our Pipeline

The generic pipeline consists of 31 products pending at FDA, 12 of which are either confirmed or potential first-to-file or first-to-market opportunities.2 We also have a number of products in various stages of development. Our pipeline is well diversified with a mix of solid-oral and alternative dosage form products across a broad range of therapeutic areas.

Our Mission

Our mission is to ensure the availability of high-quality, affordable generic pharmaceuticals and bring value to our customers while conducting our business with uncompromising integrity and ethics.

1Data as of May 1, 2015.

2Data as of March 10, 2015.

For more information, visit

Recent Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs